Matches in DBpedia 2014 for { ?s ?p Mavoglurant (AFQ-056) is an experimental drug candidate for the treatment of fragile X syndrome. It exerts its effect as an antagonist of the metabotropic glutamate receptor 5 (mGLU5).Mavoglurant is under development by Novartis and is currently in Phase II and Phase III clinical trials. If successful, it would be the first drug to treat the underlying disorder instead of the symptoms of fragile X syndrome.Mavoglurant is also in Phase II clinical trials for Levodopa-induced dyskinesia.In 2007, Norvartis had conducted a clinical study to assess its ability of reducing cigarette smoking, but no results had been published up till now. Currently Novartis is conducting a clinical trial with this drug on Obsessive Compulsive Disorder.. }
Showing items 1 to 1 of
1
with 100 items per page.
- Mavoglurant abstract "Mavoglurant (AFQ-056) is an experimental drug candidate for the treatment of fragile X syndrome. It exerts its effect as an antagonist of the metabotropic glutamate receptor 5 (mGLU5).Mavoglurant is under development by Novartis and is currently in Phase II and Phase III clinical trials. If successful, it would be the first drug to treat the underlying disorder instead of the symptoms of fragile X syndrome.Mavoglurant is also in Phase II clinical trials for Levodopa-induced dyskinesia.In 2007, Norvartis had conducted a clinical study to assess its ability of reducing cigarette smoking, but no results had been published up till now. Currently Novartis is conducting a clinical trial with this drug on Obsessive Compulsive Disorder.".